Table 1 Baseline characteristics of the study population
n = 60 | |
|---|---|
Age (years) | 64.6 ± 9.6 |
Male | 47 (78%) |
BMI (kg/m2) | 30.7 ± 5 |
Smoking status | |
Active smoker | 1 (1.7%) |
Former smoker | 33 (55%) |
Never smoker | 26 (43.3%) |
Comorbidities before SARS-CoV-2 infection | |
Obesity (BMI > 30) | 33 (55%) |
Cardiovascular | |
Ischemic heart disease | 5 (8.3%) |
Hypertension | 28 (46.7%) |
Dyslipidemia | 21 (35%) |
Diabetes | 15 (25%) |
Respiratory diseases | |
COPD | 5 (8.3%) |
Asthma | 6 (10%) |
Sleep apnea | 12 (20%) |
Thromboembolic disease | |
Deep vein thrombosis | 3 (5%) |
Pulmonary embolism | 0 (0.0%) |
Initial hospital management | |
Intensive care unit | |
Length of ICU stay (days) | 21.2 ± 12.4 |
SAPS | 35.6 ± 9.1** |
ARDS£ | 54 (90%) |
PaO2/FiO2 | 157.5 (106.6–216.1)*** |
High-flow nasal oxygen before endotracheal intubation | 6 (10%) |
Endotracheal intubation with mechanical ventilation | 54 (90%) |
Duration of endotracheal intubation (days) | 16 (10.7–26.2) |
Neuromuscular blocking agents | 53 (89.8%)* |
High-dose steroids | 27 (45%) |
Anticoagulant therapy | 55 (91.7%) |
Prone position | 47 (79.7%)* |
Pulmonary embolism | 16 (26.7%) |
DDimers (ng/ml) | 2760 (1601–4507)**** |
Fibrinogen (g/L) | 5.06 ± 1.16 |
Creatinine (mg/dl) | 87.0 (71–117) |
CRP (mg/ml) | 199.8 ± 94.6 |
Total WBC count (109/L) | 5.4 ± 1.3 |
Pulmonology unit stay (days) | 48.9 ± 36.5 |
Total length of stay (days) | 68.1 ± 45.5 |
Rehabilitation center | 39 (65%) |
Home care physiotherapy | 9 (15%) |